Logo

Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19

Share this

Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19

Shots:

  • Eli Lilly initiates P-III BLAZE-2 study assessing LY-CoV555 to prevent SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the US (skilled nursing facilities- commonly referred to as nursing homes- and assisted living facilities)
  • The company will enroll up to ~2400 patients and test whether a single dose of LY-CoV555 reduces the rate of SARS-CoV-2 infection @4wks. as well as complications of COVID-19 @8wks.
  • LY-CoV555 is a potent- neutralizing IgG1 mAb- directed against the spike protein of SARS-CoV-2. The therapy emerges from the collaboration b/w Lilly and AbCellera to create Ab therapies for the prevention & treatment of COVID-19

­ Ref: Eli Lilly | Image: Eli Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions